Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines

Ramucirumab is approved both as monotherapy and in combination with Paclitaxel for advanced gastric cancer in patients with disease progression after chemotherapy. In tumor cells, the VEGFA-VEGFR2 binding activates autocrine survival and migration signaling in angiogenesis independent manner. The pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Refolo, Maria Grazia, Lotesoriere, Claudio, Lolli, Ivan Roberto, Messa, Caterina, D’Alessandro, Rosalba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188894/
https://www.ncbi.nlm.nih.gov/pubmed/32346056
http://dx.doi.org/10.1038/s41598-020-64195-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188894/
https://www.ncbi.nlm.nih.gov/pubmed/32346056
http://dx.doi.org/10.1038/s41598-020-64195-x

Ejemplares similares